Search results
Added:
1 year ago
THT Conference 2025 - Positive safety and efficacy outcomes were found of the Reprieve decongestion management system (DMS; Reprieve Cardiovascular, Inc) for the treatment of acute decompensated heart failure (ADHF). Urinary sodium excretion was seen to be significantly higher in the Reprieve DMS arm than in the control arm, and there were fewer UTI infections in ADHF patients receiving the…
View more
Added:
6 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents results from the POLY-HF trial (NCT04633005), evaluating a polypill strategy combining multiple evidence-based medications for heart failure with reduced ejection fraction.This single-center randomized trial enrolled 212 patients with HFrEF (ejection fraction ≤40%) who were not…
View more
Obesity in Focus
Added:
8 months ago
Video
Added:
1 year ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,…
View more
Added:
2 years ago
HFA 24 - We are joined onsite by Dr Michael Kiernan (Tufts University School of Medicine, US) to discuss the findings from the PROACTIVE-HF Trial.PROACTIVE-HF is a prospective, multicenter, open-label single arm trial which aimed to assess the device safety and efficacy of the Cordella Pulmonary Artery Sensor System in a population of 529 New-York Heart Association (NYHA) class III heart failure…
View more
Added:
1 week ago
HFA Congress 2026 — Dr Guillaume Baudry (University Hospital of Brabois, Nancy, FR) joins us to discuss findings from the UF-CARE trial, evaluating ultrafiltration against enhanced medical therapy in patients with type 2 cardiorenal syndrome.This randomised, open-label study enrolled patients with severe, refractory heart failure and concurrent chronic kidney disease, a population with a high…
View more
Added:
4 days ago
HFA Congress 2026 - Dr Kevin Damman (University Medical Centre Groningen, Groningen, NL) joins us to discuss findings from a study-level meta-analysis combining data from the DECISION, DIGIT-HF and DIG trials to evaluate the role of digitalis glycosides (digoxin and digitoxin) in heart failure with reduced and mildly reduced ejection fraction.This analysis brings together evidence from three…
View more
Added:
6 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview…
View more
Added:
1 year ago
Prof Gianluigi Savarese presents a case study of a HFrEF patient with a history of disease progression and worsening of symptoms despite GDMT. The patient is admitted for IV diuresis and Professor Savarese asks, ‘what are the next steps in managing this patient?' Watch the second case by Gianluigi Savarese on Worsening Heart Failure – Outpatient Setting and a case from Javed Butler who present on…
View more
Added:
6 months ago
AHA Scientific Sessions 2025 - Dr Clyde Yancy (Northwestern University, US) joins us to explore the future trajectory of heart failure management, examining how prevention strategies, precision medicine approaches, and the evolving responsibilities of cardiologists are reshaping patient outcomes.Interview Questions:Looking at the current state of heart failure management, what do you see as the…
View more